29 results on '"Chen, Zhiwei"'
Search Results
2. Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2.
- Author
-
Luo M, Zhou B, Reddem ER, Tang B, Chen B, Zhou R, Liu H, Liu L, Katsamba PS, Au KK, Man HO, To KK, Yuen KY, Shapiro L, Dang S, Ho DD, and Chen Z
- Subjects
- Humans, Broadly Neutralizing Antibodies, BNT162 Vaccine, Breakthrough Infections, Adaptive Immunity, Antibodies, Viral, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus genetics, SARS-CoV-2, COVID-19
- Abstract
ABSTRACT Increasing spread by SARS-CoV-2 Omicron variants challenges existing vaccines and broadly reactive neutralizing antibodies (bNAbs) against COVID-19. Here we determine the diversity, potency, breadth and structural insights of bNAbs derived from memory B cells of BNT162b2-vaccinee after homogeneous Omicron BA.1 breakthrough infection. The infection activates diverse memory B cell clonotypes for generating potent class I/II and III bNAbs with new epitopes mapped to the receptor-binding domain (RBD). The top eight bNAbs neutralize wildtype and BA.1 potently but display divergent IgH/IgL sequences and neuralization profiles against other variants of concern (VOCs). Two of them (P2D9 and P3E6) belonging to class III NAbs display comparable potency against BA.4/BA.5, although structural analysis reveals distinct modes of action. P3E6 neutralizes all variants tested through a unique bivalent interaction with two RBDs. Our findings provide new insights into hybrid immunity on BNT162b2-induced diverse memory B cells in response to Omicron breakthrough infection for generating diverse bNAbs with distinct structural basis.
- Published
- 2023
- Full Text
- View/download PDF
3. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.
- Author
-
Wang P, Casner RG, Nair MS, Yu J, Guo Y, Wang M, Chan JF, Cerutti G, Iketani S, Liu L, Sheng Z, Chen Z, Yuen KY, Kwong PD, Huang Y, Shapiro L, and Ho DD
- Subjects
- Animals, Broadly Neutralizing Antibodies immunology, COVID-19, Chlorocebus aethiops, Cryoelectron Microscopy, Epitopes immunology, HEK293 Cells, Humans, Neutralization Tests, Protein Interaction Domains and Motifs, Protein Structure, Tertiary, Vero Cells, Antibodies, Monoclonal immunology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, SARS-CoV-2 immunology
- Abstract
The repeated emergence of highly pathogenic human coronaviruses as well as their evolving variants highlight the need to develop potent and broad-spectrum antiviral therapeutics and vaccines. By screening monoclonal antibodies (mAbs) isolated from COVID-19-convalescent patients, we found one mAb, 2-36, with cross-neutralizing activity against SARS-CoV. We solved the cryo-EM structure of 2-36 in complex with SARS-CoV-2 or SARS-CoV spike, revealing a highly conserved epitope in the receptor-binding domain (RBD). Antibody 2-36 neutralized not only all current circulating SARS-CoV-2 variants and SARS-COV, but also a panel of bat and pangolin sarbecoviruses that can use human angiotensin-converting enzyme 2 (ACE2) as a receptor. We selected 2-36-escape viruses in vitro and confirmed that K378 T in SARS-CoV-2 RBD led to viral resistance. Taken together, 2-36 represents a strategic reserve drug candidate for the prevention and treatment of possible diseases caused by pre-emergent SARS-related coronaviruses. Its epitope defines a promising target for the development of a pan-sarbecovirus vaccine.
- Published
- 2022
- Full Text
- View/download PDF
4. Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2.
- Author
-
Peng Q, Zhou R, Liu N, Wang H, Xu H, Zhao M, Yang D, Au KK, Huang H, Liu L, and Chen Z
- Subjects
- Animals, Humans, Mice, Antibodies, Neutralizing, Antibodies, Viral, Mice, Inbred BALB C, Mutation, Neutralization Tests, COVID-19 immunology, COVID-19 virology, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus immunology
- Abstract
Mutations in SARS-CoV-2 variants of concern (VOCs) have enhanced transmissibility and immune evasion with respect to current vaccines and neutralizing antibodies (NAbs). How naturally occurring spike mutations affect the infectivity and antigenicity of VOCs remains to be investigated. The entry efficiency of individual spike mutations was determined in vitro using pseudotyped viruses. BALB/c mice were immunized with 2-dose DNA vaccines encoding B.1.1.7, B.1.351, B.1.1.529 and their single mutations. Cellular and humoral immune responses were then compared to determine the impact of individual mutations on immunogenicity. In the B.1.1.7 lineage, Del69-70 and Del 144 in NTD, A570D and P681H in SD1 and S982A and D1118H in S2 significantly increased viral entry, whereas T716I resulted in a decrease. In the B.1.351 lineage, L18F and Del 242-244 in the NTD, K417N in the RBD and A701V in S2 also increased viral entry. S982A weakened the generation of binding antibodies. All sera showed reduced cross-neutralization activity against B.1.351, B.1.617.2 (Delta) and B.1.1.529 (Omicron BA.1). S982A, L18F, and Del 242-244 hindered the induction of cross-NAbs, whereas Del 69-70, Del144, R246I, and K417N showed the opposite effects. B.1.351 elicited adequate broad cross-NAbs against both B.1.351 and B.1.617.2. All immunogens tested, however, showed low neutralization against circulating B.1.1.529. In addition, T-cell responses were unlikely affected by mutations tested in the spike. We conclude that individual spike mutations influence viral infectivity and vaccine immunogenicity. Designing VOC-targeted vaccines is likely necessary to overcome immune evasion from current vaccines and neutralizing antibodies., (© 2022. The Author(s), under exclusive licence to CSI and USTC.)
- Published
- 2022
- Full Text
- View/download PDF
5. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
- Author
-
Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L, and Ho DD
- Subjects
- Antibodies, Neutralizing immunology, Antibodies, Neutralizing therapeutic use, COVID-19 Vaccines immunology, Humans, Immunization, Secondary, Receptors, Virus metabolism, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus metabolism, Antibodies, Viral immunology, Antibodies, Viral therapeutic use, Antigenic Drift and Shift genetics, Antigenic Drift and Shift immunology, COVID-19 immunology, COVID-19 virology, Mutation, SARS-CoV-2 classification, SARS-CoV-2 genetics, SARS-CoV-2 immunology
- Abstract
SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have surged notably to become dominant in the United States and South Africa, respectively
1,2 . These new subvariants carrying further mutations in their spike proteins raise concerns that they may further evade neutralizing antibodies, thereby further compromising the efficacy of COVID-19 vaccines and therapeutic monoclonals. We now report findings from a systematic antigenic analysis of these surging Omicron subvariants. BA.2.12.1 is only modestly (1.8-fold) more resistant to sera from vaccinated and boosted individuals than BA.2. However, BA.4/5 is substantially (4.2-fold) more resistant and thus more likely to lead to vaccine breakthrough infections. Mutation at spike residue L452 found in both BA.2.12.1 and BA.4/5 facilitates escape from some antibodies directed to the so-called class 2 and 3 regions of the receptor-binding domain3 . The F486V mutation found in BA.4/5 facilitates escape from certain class 1 and 2 antibodies but compromises the spike affinity for the viral receptor. The R493Q reversion mutation, however, restores receptor affinity and consequently the fitness of BA.4/5. Among therapeutic antibodies authorized for clinical use, only bebtelovimab retains full potency against both BA.2.12.1 and BA.4/5. The Omicron lineage of SARS-CoV-2 continues to evolve, successively yielding subvariants that are not only more transmissible but also more evasive to antibodies., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
6. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope.
- Author
-
Wang X, Chen X, Tan J, Yue S, Zhou R, Xu Y, Lin Y, Yang Y, Zhou Y, Deng K, Chen Z, Ye L, and Zhu Y
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, Cryoelectron Microscopy, Epitopes, Humans, Polysaccharides, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2
- Abstract
The SARS-CoV-2 Omicron variant harbors more than 30 mutations in the spike protein, leading to immune evasion from many therapeutic neutralizing antibodies. We reveal that a receptor-binding domain (RBD)-targeting monoclonal antibody, 35B5, exhibits potent neutralizing efficacy to Omicron. Cryo-electron microscopy structures of the extracellular domain trimer of Omicron spike with 35B5 Fab reveal that Omicron spike exhibits tight trimeric packing and high thermostability, as well as significant antigenic shifts and structural changes, within the RBD, N-terminal domain (NTD), and subdomains 1 and 2. However, these changes do not affect targeting of the invariant 35B5 epitope. 35B5 potently neutralizes SARS-CoV-2 Omicron and other variants by causing significant conformational changes within a conserved N-glycan switch that controls the transition of RBD from the "down" state to the "up" state, which allows recognition of the host entry receptor ACE2. This mode of action and potent neutralizing capacity of 35B5 indicate its potential therapeutic application for SARS-CoV-2., Competing Interests: Declaration of interests The patent of 35B5 has been licensed. K.D. and Y. Zhu are listed as inventors of the patent., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
7. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses.
- Author
-
Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L, and Ho DD
- Subjects
- Antibodies, Viral, Humans, Immunoglobulin Isotypes, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2
- Abstract
The devastation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made clear the importance of pandemic preparedness. To address future zoonotic outbreaks due to related viruses in the sarbecovirus subgenus, we identified a human monoclonal antibody, 10-40, that neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo. Comparative studies with other receptor-binding domain (RBD)-directed antibodies showed 10-40 to have the greatest breadth against sarbecoviruses, suggesting that 10-40 is a promising agent for pandemic preparedness. Moreover, structural analyses on 10-40 and similar antibodies not only defined an epitope cluster in the inner face of the RBD that is well conserved among sarbecoviruses but also uncovered a distinct antibody class with a common CDRH3 motif. Our analyses also suggested that elicitation of this class of antibodies may not be overly difficult, an observation that bodes well for the development of a pan-sarbecovirus vaccine.
- Published
- 2022
- Full Text
- View/download PDF
8. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals.
- Author
-
Ye ZW, Ong CP, Tang K, Fan Y, Luo C, Zhou R, Luo P, Cheng Y, Gray VS, Wang P, Chu H, Chan JF, To KK, Chen H, Chen Z, Yuen KY, Ling GS, Yuan S, and Jin DY
- Subjects
- Administration, Intranasal, Animals, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, Cricetinae, Mice, Mice, Transgenic, Spike Glycoprotein, Coronavirus, Vaccines, Attenuated genetics, COVID-19 prevention & control, SARS-CoV-2
- Abstract
Live attenuated vaccines might elicit mucosal and sterilizing immunity against SARS-CoV-2 that the existing mRNA, adenoviral vector and inactivated vaccines fail to induce. Here, we describe a candidate live attenuated vaccine strain of SARS-CoV-2 in which the NSP16 gene, which encodes 2'-O-methyltransferase, is catalytically disrupted by a point mutation. This virus, designated d16, was severely attenuated in hamsters and transgenic mice, causing only asymptomatic and nonpathogenic infection. A single dose of d16 administered intranasally resulted in sterilizing immunity in both the upper and lower respiratory tracts of hamsters, thus preventing viral spread in a contact-based transmission model. It also robustly stimulated humoral and cell-mediated immune responses, thus conferring full protection against lethal challenge with SARS-CoV-2 in a transgenic mouse model. The neutralizing antibodies elicited by d16 effectively cross-reacted with several SARS-CoV-2 variants. Secretory immunoglobulin A was detected in the blood and nasal wash of vaccinated mice. Our work provides proof-of-principle evidence for harnessing NSP16-deficient SARS-CoV-2 for the development of live attenuated vaccines and paves the way for further preclinical studies of d16 as a prototypic vaccine strain, to which new features might be introduced to improve safety, transmissibility, immunogenicity and efficacy., (© 2022. The Author(s), under exclusive licence to CSI and USTC.)
- Published
- 2022
- Full Text
- View/download PDF
9. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong.
- Author
-
Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, Huang H, Yang D, Au KK, Wang H, Man K, Yuen KY, and Chen Z
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, BNT162 Vaccine, CD8-Positive T-Lymphocytes, Hong Kong epidemiology, Humans, Immunity, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, SARS-CoV-2 genetics
- Abstract
Background: Nearly 4 billion doses of the BNT162b2-mRNA and CoronaVac-inactivated vaccines have been administrated globally, yet different vaccine-induced immunity against SARS-CoV-2 variants of concern (VOCs) remain incompletely investigated., Methods: We compare the immunogenicity and durability of these two vaccines among fully vaccinated Hong Kong people., Findings: Standard BNT162b2 and CoronaVac vaccinations were tolerated and induced neutralizing antibody (NAb) (100% and 85.7%) and spike-specific CD4 T cell responses (96.7% and 82.1%), respectively. The geometric mean NAb IC
50 and median frequencies of reactive CD4 subsets were consistently lower among CoronaVac-vaccinees than BNT162b2-vaccinees. CoronaVac did not induce measurable levels of nucleocapsid protein-specific IFN-γ+ CD4+ T or IFN-γ+ CD8+ T cells compared with unvaccinated. Against VOCs, NAb response rates and geometric mean IC50 titers against B.1.617.2 (Delta) and B.1.1.529 (Omicron) were significantly lower for CoronaVac (50%, 23.2 and 7.1%, <20) than BNT162b2 (94.1%, 131 and 58.8%, 35.0), respectively. Three months after vaccinations, NAbs to VOCs dropped near to detection limit, along with waning memory T cell responses, mainly among CoronaVac-vaccinees., Interpretation: Our results indicate that vaccinees especially CoronaVac-vaccinees with significantly reduced NAbs may probably face higher risk to pandemic VOCs breakthrough infection., Funding: This study was supported by the Hong Kong Research Grants Council Collaborative Research Fund (C7156-20GF and C1134-20GF); the Wellcome Trust (P86433); the National Program on Key Research Project of China (Grant 2020YFC0860600, 2020YFA0707500 and 2020YFA0707504); Shenzhen Science and Technology Program (JSGG20200225151410198 and JCYJ20210324131610027); HKU Development Fund and LKS Faculty of Medicine Matching Fund to AIDS Institute; Hong Kong Innovation and Technology Fund, Innovation and Technology Commission and generous donation from the Friends of Hope Education Fund. Z.C.'s team was also partly supported by the Theme-Based Research Scheme (T11-706/18-N)., Competing Interests: Declaration of interest The authors declare no competing interests., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
10. Vaccine-breakthrough infection by the SARS-CoV-2 omicron variant elicits broadly cross-reactive immune responses.
- Author
-
Zhou R, To KK, Peng Q, Chan JM, Huang H, Yang D, Lam BH, Chuang VW, Cai JP, Liu N, Au KK, Tsang OT, Yuen KY, and Chen Z
- Subjects
- Adult, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Cross Reactions, Female, Humans, Male, COVID-19 immunology, COVID-19 Vaccines immunology, SARS-CoV-2 immunology
- Published
- 2022
- Full Text
- View/download PDF
11. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models.
- Author
-
Zhou R, Wang P, Wong YC, Xu H, Lau SY, Liu L, Mok BW, Peng Q, Liu N, Woo KF, Deng S, Tam RC, Huang H, Zhang AJ, Zhou D, Zhou B, Chan CY, Du Z, Yang D, Au KK, Yuen KY, Chen H, and Chen Z
- Subjects
- Administration, Intranasal, Animals, COVID-19 genetics, COVID-19 immunology, Chlorocebus aethiops, Disease Models, Animal, Dogs, Female, HEK293 Cells, Humans, Immunity, Mucosal, Madin Darby Canine Kidney Cells, Male, Mice, Mice, Inbred BALB C, Mice, Transgenic, Vaccines, Attenuated genetics, Vaccines, Attenuated immunology, Vero Cells, COVID-19 prevention & control, COVID-19 Vaccines genetics, COVID-19 Vaccines immunology, Immunization, Secondary, Influenza Vaccines genetics, Influenza Vaccines immunology, SARS-CoV-2 genetics, SARS-CoV-2 immunology, Vaccines, DNA genetics, Vaccines, DNA immunology
- Abstract
Background: Vaccines in emergency use are efficacious against COVID-19, yet vaccine-induced prevention against nasal SARS-CoV-2 infection remains suboptimal., Methods: Since mucosal immunity is critical for nasal prevention, we investigated the efficacy of an intramuscular PD1-based receptor-binding domain (RBD) DNA vaccine (PD1-RBD-DNA) and intranasal live attenuated influenza-based vaccines (LAIV-CA4-RBD and LAIV-HK68-RBD) against SARS-CoV-2., Findings: Substantially higher systemic and mucosal immune responses, including bronchoalveolar lavage IgA/IgG and lung polyfunctional memory CD8 T cells, were induced by the heterologous PD1-RBD-DNA/LAIV-HK68-RBD as compared with other regimens. When vaccinated animals were challenged at the memory phase, prevention of robust SARS-CoV-2 infection in nasal turbinate was achieved primarily by the heterologous regimen besides consistent protection in lungs. The regimen-induced antibodies cross-neutralized variants of concerns. Furthermore, LAIV-CA4-RBD could boost the BioNTech vaccine for improved mucosal immunity., Interpretation: Our results demonstrated that intranasal influenza-based boost vaccination induces mucosal and systemic immunity for effective SARS-CoV-2 prevention in both upper and lower respiratory systems., Funding: This study was supported by the Research Grants Council Collaborative Research Fund, General Research Fund and Health and Medical Research Fund in Hong Kong; Outbreak Response to Novel Coronavirus (COVID-19) by the Coalition for Epidemic Preparedness Innovations; Shenzhen Science and Technology Program and matching fund from Shenzhen Immuno Cure BioTech Limited; the Health@InnoHK, Innovation and Technology Commission of Hong Kong; National Program on Key Research Project of China; donations from the Friends of Hope Education Fund; the Theme-Based Research Scheme., Competing Interests: Declaration of interests H.C., Z.C. and KY.Y. are co-inventors of PD1-based and LAIV-based COVID-19 vaccine patent. YC. W. and L.L are co-inventors of PD1-based COVID-19 vaccine, P.W. is co-inventors of LAIV-based COVID-19 vaccine. The other authors declare no competing interests. YC. W. is now working at Immuno Cure Holding (HK) Limited., (Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters.
- Author
-
Zhang BZ, Wang X, Yuan S, Li W, Dou Y, Poon VK, Chan CC, Cai JP, Chik KK, Tang K, Chan CC, Hu YF, Hu JC, Badea SR, Gong HR, Lin X, Chu H, Li X, To KK, Liu L, Chen Z, Hung IF, Yuen KY, Chan JF, and Huang JD
- Subjects
- Animals, Cricetinae, Female, HEK293 Cells, Humans, Male, Mesocricetus, Mice, Mice, Inbred BALB C, Vaccination, COVID-19 prevention & control, COVID-19 Vaccines immunology, Immunodominant Epitopes immunology, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and in vivo protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
13. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.
- Author
-
Zhang Q, Ju B, Ge J, Chan JF, Cheng L, Wang R, Huang W, Fang M, Chen P, Zhou B, Song S, Shan S, Yan B, Zhang S, Ge X, Yu J, Zhao J, Wang H, Liu L, Lv Q, Fu L, Shi X, Yuen KY, Liu L, Wang Y, Chen Z, Zhang L, Wang X, and Zhang Z
- Subjects
- Angiotensin-Converting Enzyme 2 metabolism, Animals, Binding Sites immunology, COVID-19 immunology, Cricetinae, Disease Models, Animal, Epitopes immunology, Female, Humans, Male, Neutralization Tests, Receptors, Antigen, B-Cell immunology, Spike Glycoprotein, Coronavirus immunology, Angiotensin-Converting Enzyme 2 immunology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Receptors, Virus immunology, SARS-CoV-2 immunology
- Abstract
Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical interventions against COVID-19 disease. However, their common genetic and biologic features remain elusive. Here we interrogate a total of 165 antibodies from eight COVID-19 patients, and find that potent nAbs from different patients have disproportionally high representation of IGHV3-53/3-66 usage, and therefore termed as public antibodies. Crystal structural comparison of these antibodies reveals they share similar angle of approach to RBD, overlap in buried surface and binding residues on RBD, and have substantial spatial clash with receptor angiotensin-converting enzyme-2 (ACE2) in binding to RBD. Site-directed mutagenesis confirms these common binding features although some minor differences are found. One representative antibody, P5A-3C8, demonstrates extraordinarily protective efficacy in a golden Syrian hamster model against SARS-CoV-2 infection. However, virus escape analysis identifies a single natural mutation in RBD, namely K417N found in B.1.351 variant from South Africa, abolished the neutralizing activity of these public antibodies. The discovery of public antibodies and shared escape mutation highlight the intricate relationship between antibody response and SARS-CoV-2, and provide critical reference for the development of antibody and vaccine strategies to overcome the antigenic variation of SARS-CoV-2., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
14. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
- Author
-
Li M, Guo J, Lu S, Zhou R, Shi H, Shi X, Cheng L, Liang Q, Liu H, Wang P, Wang N, Wang Y, Fu L, Xing M, Wang R, Ju B, Liu L, Lau SY, Jia W, Tong X, Yuan L, Guo Y, Qi H, Zhang Q, Huang Z, Chen H, Zhang Z, Chen Z, Peng X, Zhou D, and Zhang L
- Subjects
- Adenovirus Vaccines immunology, Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, COVID-19 virology, COVID-19 Vaccines immunology, Cricetinae, Disease Models, Animal, Female, HEK293 Cells, Humans, Male, Mice, Mice, Inbred BALB C, Pan troglodytes, RNA, Viral blood, Spike Glycoprotein, Coronavirus immunology, Transfection, Treatment Outcome, Adenovirus Vaccines administration & dosage, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Immunization Schedule, Immunogenicity, Vaccine, SARS-CoV-2 immunology, Vaccination methods
- Abstract
The development of a safe and effective vaccine against SARS-CoV-2, the causative agent of pandemic coronavirus disease-2019 (COVID-19), is a global priority. Here, we aim to develop novel SARS-CoV-2 vaccines based on a derivative of less commonly used rare adenovirus serotype AdC68 vector. Three vaccine candidates were constructed expressing either the full-length spike (AdC68-19S) or receptor-binding domain (RBD) with two different signal sequences (AdC68-19RBD and AdC68-19RBDs). Single-dose intramuscular immunization induced robust and sustained binding and neutralizing antibody responses in BALB/c mice up to 40 weeks after immunization, with AdC68-19S being superior to AdC68-19RBD and AdC68-19RBDs. Importantly, immunization with AdC68-19S induced protective immunity against high-dose challenge with live SARS-CoV-2 in a golden Syrian hamster model of SARS-CoV-2 infection. Vaccinated animals demonstrated dramatic decreases in viral RNA copies and infectious virus in the lungs, as well as reduced lung pathology compared to the control animals. Similar protective effects were also found in rhesus macaques. Taken together, these results confirm that AdC68-19S can induce protective immune responses in experimental animals, meriting further development toward a human vaccine against SARS-CoV-2., Competing Interests: The authors declare that LZ, DZ, ML, and XS are co-inventors on pending patent applications related to the AdC68-19S, AdC68-19RBD, and AdC68-19RBDs vaccine candidates. ZH, XT, and LY are employees of Walvax Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Li, Guo, Lu, Zhou, Shi, Shi, Cheng, Liang, Liu, Wang, Wang, Wang, Fu, Xing, Wang, Ju, Liu, Lau, Jia, Tong, Yuan, Guo, Qi, Zhang, Huang, Chen, Zhang, Chen, Peng, Zhou and Zhang.)
- Published
- 2021
- Full Text
- View/download PDF
15. Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein.
- Author
-
Wang P, Lau SY, Deng S, Chen P, Mok BW, Zhang AJ, Lee AC, Chan KH, Tam RC, Xu H, Zhou R, Song W, Liu L, To KK, Chan JF, Chen Z, Yuen KY, and Chen H
- Subjects
- Animals, COVID-19 immunology, COVID-19 virology, Cell Line, Tumor, Chlorocebus aethiops, Cricetinae, Cytokines immunology, Cytokines metabolism, Female, Host-Pathogen Interactions, Humans, Male, Mesocricetus, Mice, Inbred BALB C, SARS-CoV-2 immunology, SARS-CoV-2 pathogenicity, T-Lymphocytes immunology, T-Lymphocytes metabolism, Vero Cells, Virulence genetics, Virulence immunology, Mice, COVID-19 diagnosis, Mutation, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus genetics, Virus Replication genetics
- Abstract
SARS-CoV-2 is of zoonotic origin and contains a PRRA polybasic cleavage motif which is considered critical for efficient infection and transmission in humans. We previously reported on a panel of attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction of the spike protein. Here, we characterize pathogenicity, immunogenicity, and protective ability of a further cell-adapted SARS-CoV-2 variant, Ca-DelMut, in in vitro and in vivo systems. Ca-DelMut replicates more efficiently than wild type or parental virus in Vero E6 cells, but causes no apparent disease in hamsters, despite replicating in respiratory tissues. Unlike wild type virus, Ca-DelMut causes no obvious pathological changes and does not induce elevation of proinflammatory cytokines, but still triggers a strong neutralizing antibody and T cell response in hamsters and mice. Ca-DelMut immunized hamsters challenged with wild type SARS-CoV-2 are fully protected, with little sign of virus replication in the upper or lower respiratory tract, demonstrating sterilizing immunity.
- Published
- 2021
- Full Text
- View/download PDF
16. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
- Author
-
Yeung ML, Teng JLL, Jia L, Zhang C, Huang C, Cai JP, Zhou R, Chan KH, Zhao H, Zhu L, Siu KL, Fung SY, Yung S, Chan TM, To KK, Chan JF, Cai Z, Lau SKP, Chen Z, Jin DY, Woo PCY, and Yuen KY
- Subjects
- COVID-19 immunology, COVID-19 virology, Cell Line, Humans, Protein Binding, Angiotensin-Converting Enzyme 2 immunology, Host Microbial Interactions immunology, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, Vasopressins immunology, Virus Internalization
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause acute respiratory disease and multiorgan failure. Finding human host factors that are essential for SARS-CoV-2 infection could facilitate the formulation of treatment strategies. Using a human kidney cell line-HK-2-that is highly susceptible to SARS-CoV-2, we performed a genome-wide RNAi screen and identified virus dependency factors (VDFs), which play regulatory roles in biological pathways linked to clinical manifestations of SARS-CoV-2 infection. We found a role for a secretory form of SARS-CoV-2 receptor, soluble angiotensin converting enzyme 2 (sACE2), in SARS-CoV-2 infection. Further investigation revealed that SARS-CoV-2 exploits receptor-mediated endocytosis through interaction between its spike with sACE2 or sACE2-vasopressin via AT1 or AVPR1B, respectively. Our identification of VDFs and the regulatory effect of sACE2 on SARS-CoV-2 infection shed insight into pathogenesis and cell entry mechanisms of SARS-CoV-2 as well as potential treatment strategies for COVID-19., Competing Interests: Declaration of interests J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declare no competing interests., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
17. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.
- Author
-
Zhou D, Chan JF, Zhou B, Zhou R, Li S, Shan S, Liu L, Zhang AJ, Chen SJ, Chan CC, Xu H, Poon VK, Yuan S, Li C, Chik KK, Chan CC, Cao J, Chan CY, Kwan KY, Du Z, Lau TT, Zhang Q, Zhou J, To KK, Zhang L, Ho DD, Yuen KY, and Chen Z
- Subjects
- Angiotensin-Converting Enzyme 2 physiology, Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, COVID-19 immunology, COVID-19 virology, Cricetinae, Female, HEK293 Cells, Humans, Male, Mesocricetus, Viral Load, Antibodies, Neutralizing therapeutic use, Antibodies, Viral therapeutic use, COVID-19 therapy, SARS-CoV-2 immunology, Turbinates virology
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst in the upper respiratory portal for high transmissibility. To determine human neutralizing antibodies (HuNAbs) for entry protection, we tested three potent HuNAbs (IC
50 range, 0.0007-0.35 μg/mL) against live SARS-CoV-2 infection in the golden Syrian hamster model. These HuNAbs inhibit SARS-CoV-2 infection by competing with human angiotensin converting enzyme-2 for binding to the viral receptor binding domain (RBD). Prophylactic intraperitoneal or intranasal injection of individual HuNAb or DNA vaccination significantly reduces infection in the lungs but not in the nasal turbinates of hamsters intranasally challenged with SARS-CoV-2. Although postchallenge HuNAb therapy suppresses viral loads and lung damage, robust infection is observed in nasal turbinates treated within 1-3 days. Our findings demonstrate that systemic HuNAb suppresses SARS-CoV-2 replication and injury in lungs; however, robust viral infection in nasal turbinate may outcompete the antibody with significant implications to subprotection, reinfection, and vaccine., Competing Interests: Declaration of interests J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declare no conflicts of interest except for a provisional patent application filed for human monoclonal antibodies generated in our laboratory by the University of Hong Kong. The funding sources had no role in study design, data collection, analysis, interpretation, or writing of the report., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
18. Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility.
- Author
-
Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, Chan WM, Fan Z, Tsoi HW, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai JP, Kok KH, Chu H, Chan KH, Sridhar S, Chen Z, Chen H, To KK, and Yuen KY
- Subjects
- Animals, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 blood, COVID-19 immunology, Cricetinae, Disease Models, Animal, Lung virology, Molecular Docking Simulation, Viral Load, COVID-19 pathology, SARS-CoV-2
- Abstract
Background: A physiological small-animal model that resembles COVID-19 with low mortality is lacking., Methods: Molecular docking on the binding between angiotensin-converting enzyme 2 (ACE2) of common laboratory mammals and the receptor-binding domain of the surface spike protein of SARS-CoV-2 suggested that the golden Syrian hamster is an option. Virus challenge, contact transmission, and passive immunoprophylaxis studies were performed. Serial organ tissues and blood were harvested for histopathology, viral load and titer, chemokine/cytokine level, and neutralizing antibody titer., Results: The Syrian hamster could be consistently infected by SARS-CoV-2. Maximal clinical signs of rapid breathing, weight loss, histopathological changes from the initial exudative phase of diffuse alveolar damage with extensive apoptosis to the later proliferative phase of tissue repair, airway and intestinal involvement with viral nucleocapsid protein expression, high lung viral load, and spleen and lymphoid atrophy associated with marked chemokine/cytokine activation were observed within the first week of virus challenge. The mean lung virus titer was between 105 and 107 TCID50/g. Challenged index hamsters consistently infected naive contact hamsters housed within the same cages, resulting in similar pathology but not weight loss. All infected hamsters recovered and developed mean serum neutralizing antibody titers ≥1:427 14 days postchallenge. Immunoprophylaxis with early convalescent serum achieved significant decrease in lung viral load but not in lung pathology. No consistent nonsynonymous adaptive mutation of the spike was found in viruses isolated from the infected hamsters., Conclusions: Besides satisfying Koch's postulates, this readily available hamster model is an important tool for studying transmission, pathogenesis, treatment, and vaccination against SARS-CoV-2., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
19. Clinical characteristics and immunogenicity after Omicron breakthrough infection in patients with chronic hepatitis B infection: A longitudinal observational study.
- Author
-
Zha, Guanhua, Chen, Zhiwei, Wu, Na, Huang, Tianquan, Deng, Zhiling, Cai, Dachuan, Peng, Mingli, Hu, Peng, and Ren, Hong
- Subjects
BREAKTHROUGH infections ,HEPATITIS B ,SARS-CoV-2 Omicron variant ,IMMUNE response ,COVID-19 ,CHRONIC hepatitis B - Abstract
The clinical and immunological features after breakthrough infection (BTI) during Omicron wave in patients with chronic hepatitis B virus infection (CHB) are still unclear. A total of 101 patients with CHB from our previous coronavirus disease 2019 (COVID‐19) vaccination cohort (NCT05007665), were continued to be followed up at the Second Affiliated Hospital of Chongqing Medical University after BTI, while an additional 39 healthcare workers after BTI were recruited as healthy controls (HCs). Clinical data were collected using questionnaire survey and electronic medical record. Blood samples were used to determine the antibody responses, as well as B and T cell responses. After BTI, the clinical symptoms of COVID‐19 were mild to moderate in patients with CHB, with a median duration of 5 days. Compared with HCs, patients with CHB were more susceptible to develop moderate COVID‐19. The liver function was not significantly damaged, and HBV‐DNA was not activated in patients with CHB after BTI. Patients with CHB could elicit robust antibody responses after BTI (NAbs 13.0‐fold, BA.5 IgG: 24.2‐fold, respectively), which was also significantly higher than that in every period after vaccination (all p < 0.001), and compared to that in HCs after BTI. The CD4+, cTfh, and CD8+ T cell responses were also augmented in patients with CHB after BTI, while exhibiting comparability to those observed in HCs. In patients with CHB after BTI, the immune imprint was observed in B cell responses, rather than in T cell responses. In conclusion, Omicron breakthrough infection induced mild to moderate COVID‐19 symptoms in patients with CHB, without exacerbating the progress of liver diseases. Meanwhile, BTI demonstrated the ability to induce robust antibody and T cell responses in patients with CHB, which was comparable to those observed in HCs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Dynamic immunogenicity after primary and booster inactivated SARS‐CoV‐2 vaccination in people living with HIV: A longitudinal observational study.
- Author
-
Lu, Ting, Chen, Zhiwei, Cao, Yu, Ao, Ling, Li, Zisheng, Gu, Xiaoyi, Ren, Xingqian, Wang, Yixuan, Zhang, Gaoli, Xiang, Dejuan, Chen, Min, Cai, Dachuan, Hu, Peng, Zhang, Dazhi, Peng, Mingli, Shi, Xiaofeng, and Ren, Hong
- Subjects
SARS-CoV-2 ,HIV-positive persons ,IMMUNE response ,BOOSTER vaccines ,VACCINATION - Abstract
People living with HIV (PLWH) have poor outcomes from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2); vaccination reduces the associated mortality. The humoral immune response dynamics after booster inactivated vaccinations in PLWH remain unclear. In this longitudinal observational study, 100 PLWH after primary inactivated SARS‐CoV‐2 vaccination were consecutively recruited and followed up. After booster vaccination (BV), neutralizing antibodies (NAbs) were detected at 1 month from all the PLWH, and the titer increased sixfold compared to that associated with the primary vaccination (PV), similar to that in healthy controls after BV. The NAbs titer declined over time after BV, but remained higher at 6 months than after PV. The NAbs response was elevated after BV with CD4 count <200 cells/μL, it was the poorest among the different CD4 cell count subgroups. Similar results were observed for anti‐RBD‐IgG responses. Moreover, RBD‐specific MBCs were significantly elevated after BV in PLWH. No serious AEs were observed after BV in PLWH. In conclusion, booster inactivated SARS‐CoV‐2 vaccination is well tolerated and can elicit robust and durable humoral responses in PLWH. PLWH may benefit from a third dose of the inactivated vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Humoral responses after primary and booster SARS‐CoV‐2 inactivated vaccination in patients with chronic hepatitis B virus infection: A longitudinal observational study.
- Author
-
Chen, Zhiwei, Huang, Tianquan, He, Taiyu, Zha, Guanhua, Zhu, Qian, Zhang, Gaoli, Xiang, Dejuan, Chen, Min, Li, Hu, Ling, Ning, Lan, Yinghua, Shi, Xiaofeng, Zhang, Dazhi, Xu, Pan, Pan, Qingbo, Song, Rui, Cao, Junxiong, Zhang, Yingzhi, Xiang, Hongyan, and Feng, Yali
- Subjects
HEPATITIS B ,SARS-CoV-2 ,CHRONIC hepatitis B ,SARS-CoV-2 Omicron variant ,BOOSTER vaccines - Abstract
Given the pandemic of severe acute respiratory syndrome coronavirus 2 Omicron variants, booster vaccination (BV) using inactivated virus vaccines (the third dose) has been implemented in China. However, the immune responses after BV, especially those against Omicron, in patients with chronic hepatitis B virus (HBV) infection (CHB) are unclear. In this prospective longitudinal study, 114 patients with CHB and 68 healthy controls (HCs) were recruited after receiving inactivated vaccination. The anti‐receptor‐binding domain (RBD) immunoglobulin G (IgG), neutralizing antibodies (NAbs), neutralization against Omicron (BA2.12.1, BA.4/5), and specific B/T cells were evaluated. In patients, anti‐RBD IgG was elevated significantly after BV; the titers were as high as those in HCs. Similar results were obtained for the NAbs. However, compared with that against wild type (WT), the neutralization against Omicron was compromised after BV. The frequency of RBD+ atypical memory B cells increased, but spike‐specific cluster of differentiation 4+/8+ T cells remained unchanged after BV. Moreover, no serious adverse events or HBV reactivation were observed after BV. These results suggest that BV significantly enhanced antibody responses against WT; however, it resulted in compromised antibody responses against Omicron in patients with CHB. Hence, new all‐in‐one vaccines and optimal vaccination strategies should be studied promptly. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
- Author
-
Cai, Jian-Piao, Luo, Cuiting, Wang, Kun, Cao, Hehe, Chen, Lin-Lei, Zhang, Xiaojuan, Han, Yuting, Yin, Feifei, Zhang, Anna Jinxia, Chu, Hin, Yuan, Shuofeng, Kok, Kin-Hang, To, Kelvin Kai-Wang, Chen, Honglin, Chen, Zhiwei, Jin, Dong-Yan, Yuen, Kwok-Yung, and Chan, Jasper Fuk-Woo
- Subjects
VIRAL antibodies ,SARS-CoV-2 ,SARS-CoV-2 Omicron variant ,IMMUNOGLOBULINS ,COVID-19 ,VIRAL load - Abstract
The emergence of new immune-evasive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and subvariants outpaces the development of vaccines specific against the dominant circulating strains. In terms of the only accepted immune correlate of protection, the inactivated whole-virion vaccine using wild-type SARS-CoV-2 spike induces a much lower serum neutralizing antibody titre against the Omicron subvariants. Since the inactivated vaccine given intramuscularly is one of the most commonly used coronavirus disease 2019 (COVID-19) vaccines in developing regions, we tested the hypothesis that intranasal boosting after intramuscular priming would provide a broader level of protection. Here, we showed that one or two intranasal boosts with the Fc-linked trimeric spike receptor-binding domain from wild-type SARS-CoV-2 can induce significantly higher serum neutralizing antibodies against wild-type SARS-CoV-2 and the Omicron subvariants, including BA.5.2 and XBB.1, with a lower titre in the bronchoalveolar lavage of vaccinated Balb/c mice than vaccination with four intramuscular doses of inactivated whole virion vaccine. The intranasally vaccinated K18-hACE2-transgenic mice also had a significantly lower nasal turbinate viral load, suggesting a better protection of the upper airway, which is the predilected site of infection by Omicron subvariants. This intramuscular priming and intranasal boosting approach that achieves broader cross-protection against Omicron variants and subvariants may lengthen the interval required for changing the vaccine immunogen from months to years. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines.
- Author
-
Xiang, Feng, Long, Boyu, He, Jiaoxia, Cheng, Feifei, Zhang, Sijing, Liu, Qing, Chen, Zhiwei, Li, Hu, Chen, Min, Peng, Mingli, Yin, Wenwei, Liu, Dongfang, and Ren, Hong
- Subjects
B cells ,TYPE 2 diabetes ,ANTIBODY formation ,COVID-19 vaccines ,IMMUNOGLOBULINS ,COVID-19 ,BODY mass index ,SARS-CoV-2 - Abstract
Background: Patients with type 2 diabetes mellitus (T2DM) have been reported to be more susceptible to 2019 novel coronavirus (2019-nCoV) and more likely to develop severe pneumonia. However, the safety and immunological responses of T2DM patients after receiving the inactivated vaccines are not quite definite. Therefore, we aimed to explore the safety, antibody responses, and B-cell immunity of T2DM patients who were vaccinated with inactivated coronavirus disease 2019 (COVID-19) vaccines. Methods: Eighty-nine patients with T2DM and 100 healthy controls (HCs) were enrolled, all of whom had received two doses of full-course inactivated vaccines. At 21–105 days after full-course vaccines: first, the safety of the vaccines was assessed by questionnaires; second, the titers of anti-receptor binding domain IgG (anti-RBD-IgG) and neutralizing antibodies (NAbs) were measured; third, we detected the frequency of RBD-specific memory B cells (RBD-specific MBCs) to explore the cellular immunity of T2DM patients. Results: The overall incidence of adverse events was similar between T2DM patients and HCs, and no serious adverse events were recorded in either group. Compared with HCs, significantly lower titers of anti-RBD-IgG (p = 0.004) and NAbs (p = 0.013) were observed in T2DM patients. Moreover, the frequency of RBD-specific MBCs was lower in T2DM patients than in HCs (p = 0.027). Among the 89 T2DM patients, individuals with lower body mass index (BMI) had higher antibody titers (anti-RBD-IgG: p = 0.009; NAbs: p = 0.084). Furthermore, we found that sex, BMI, and days after vaccination were correlated with antibody titers. Conclusions: Inactivated COVID-19 vaccines were safe in patients with T2DM, but the antibody responses and memory B-cell responses were significantly decreased compared to HCs. Trial registration number and date: NCT05043246. September 14, 2021. (Clinical Trials.gov) [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Natural Transmission of Bat-like Severe Acute Respiratory Syndrome Coronavirus 2 Without Proline-Arginine-Arginine-Alanine Variants in Coronavirus Disease 2019 Patients.
- Author
-
Wong, Yik Chun, Lau, Siu Ying, To, Kelvin Kai Wang, Mok, Bobo Wing Yee, Li, Xin, Wang, Pui, Deng, Shaofeng, Woo, Kin Fai, Du, Zhenglong, Li, Cun, Zhou, Jie, Chan, Jasper Fuk Woo, Yuen, Kwok Yung, Chen, Honglin, and Chen, Zhiwei
- Subjects
COVID-19 ,GENETIC mutation ,ARGININE ,ALANINE ,PROLINE ,VIROLOGY ,COVID-19 testing ,POLYMERASE chain reaction - Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains the furin cleavage Proline-Arginine-Arginine-Alanine (PRRA) motif in the S1/S2 region, which enhances viral pathogenicity but is absent in closely related bat and pangolin coronaviruses. Whether bat-like coronaviral variants without PRRA (∆PRRA) can establish natural infections in humans is unknown. Methods Here, we developed a duplex digital polymerase chain reaction assay to examine ∆PRRA variants in Vero-E6-propagated isolates, human organoids, experimentally infected hamsters, and coronavirus disease 2019 (COVID-19) patients. Results We found that SARS-CoV-2, as currently transmitting in humans, contained a quasispecies of wild-type, ∆PRRA variants and variants that have mutations upstream of the PRRA motif. Moreover, the ∆PRRA variants were readily detected despite being at a low intra-host frequency in transmitted founder viruses in hamsters and in COVID-19 patients, including in acute cases and a family cluster, with a prevalence rate of 52.9%. Conclusions Our findings demonstrate that bat-like SARS-CoV-2ΔPRRA not only naturally exists but remains transmissible in COVID-19 patients, which has significant implications regarding the zoonotic origin and natural evolution of SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. T cell epitopes are largely conserved in the SARS‐CoV‐2 Omicron subvariant (BA.1, BA.2, BA.3, and GKA).
- Author
-
Li, Hu, Chen, Zhiwei, Liu, Xiaoqing, and Hu, Peng
- Subjects
SARS-CoV-2 Omicron variant ,T cells ,EPITOPES ,SARS-CoV-2 - Abstract
Conservation rates in the CD4+ T cell epitopes in the Omicron subvariants (E). gl We examined CD8 SP + sp T cell epitopes identified in three studies. T cell epitopes are largely conserved in the SARS-CoV-2 Omicron subvariant (BA.1, BA.2, BA.3, and GKA) Keywords: COVID-19; epitopes; Omicron; SARS-CoV-2 EN COVID-19 epitopes Omicron SARS-CoV-2 4591 4592 2 08/19/22 20221001 NES 221001 The SARS-CoV-2 variant Omicron (B.1.1.529) was first reported in South Africa by the World Health Organization in November 2021 and the Omicron variant is now the predominant globally prevalent variant and account for almost all sequences recently reported to GISAID.1 Choi et al.2 discovered that most T cell epitopes are conserved in the Omicron variant by comparing amino acid sequences of T cell epitopes identified from the original SARS-CoV-2 strain (Wuhan-Hu-1) in the Omicron variant (hCoV-19/South africa/CERI-KRISP-K032284/2021). [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
26. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
- Author
-
Yeung, Man Lung, Teng, Jade Lee Lee, Jia, Lilong, Zhang, Chaoyu, Huang, Chengxi, Cai, Jian-Piao, Zhou, Runhong, Chan, Kwok-Hung, Zhao, Hanjun, Zhu, Lin, Siu, Kam-Leung, Fung, Sin-Yee, Yung, Susan, Chan, Tak Mao, To, Kelvin Kai-Wang, Chan, Jasper Fuk-Woo, Cai, Zongwei, Lau, Susanna Kar Pui, Chen, Zhiwei, and Jin, Dong-Yan
- Subjects
- *
PROTEIN-protein interactions , *SARS-CoV-2 , *RENIN-angiotensin system - Published
- 2023
- Full Text
- View/download PDF
27. Ratiometric SERS sensing chip for high precision and ultra-sensitive detection of SARS-CoV-2 RNA in human saliva.
- Author
-
Lin, Xueliang, Weng, Youliang, Liu, Yi, Lin, Duo, Yang, Huishan, Chen, Zhiwei, and Feng, Shangyuan
- Subjects
- *
SALIVA , *SERS spectroscopy , *SARS-CoV-2 , *RNA , *RNA analysis , *POINT-of-care testing - Abstract
The rapid and high precision analysis of SARS-CoV-2 RNA in saliva is crucial for the efficient prevention and control of COVID-19. Herein, we developed a novel ratiometric surface-enhanced Raman spectroscopy (SERS) sensing chip based on a two-dimensional core-molecule-shell-molecule nanostructure for quantitative detection of SARS-CoV-2 RNA. Owing to the use of base-complementary pairing mechanism, this SERS sensing chip has better selectivity in discriminating SARS-CoV-2 RNA against other RNA. Besides, an internal standard molecule (4MBN) in the SERS sensing chip can used to calibrate the real-time changing Raman signals of the probe molecule during quantitative assay. Using this cleverly designed SERS sensing chip, the dynamic ranges from 10–6 M to 10–12 M with a low of detection limit (LOD = 7.61 ×10–14 M) can be acquired for detection of SARS-CoV-2 RNA. Meanwhile, this SERS sensing chip was well adapted for point-of-care testing (POCT) in combination with portable Raman spectrometer, which is expected to achieve effective detection of early SARS-CoV-2 infection. [Display omitted] • A ratiometric SERS chip was developed for quantitative detection of SARS-CoV-2 RNA. • The internal standard molecule was used to correct the fluctuating signal of probe in real time. • The LOD of 7.61 × 10–14 M can be obtained by portable Raman spectrometer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. A novel photoelectrochemical immunosensor based on TiO2@Bi2WO6 hollow microspheres and Ag2S for sensitive detection of SARS-COV-2 nucleocapsid protein.
- Author
-
Chang, Huiqin, Jiang, Meng, Zhu, Qiying, Liu, Anqi, Wu, Yuyin, Li, Canguo, Ji, Xiangyue, Gong, Li, Li, Shanshan, Chen, Zhiwei, Kong, Ling, and Han, Lei
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *SILVER sulfide - Abstract
The synthesis of TiO 2 @Bi 2 WO 6 hollow microspheres and schematic diagram of the label-free PEC immunosensor fabrication process. The electron-transfer mechanism of the PEC immunosensor: band gap matching of the substrate, the enhancement effect of TiO 2 @Bi 2 WO 6 synthesized by the modification strategy, and the blocking effect of biological macromolecules inhibit the transfer of electrons. [Display omitted] • A label-free PEC immunosensor based on TiO 2 @Bi 2 WO 6 and Ag 2 S was developed successfully. • TiO 2 @Bi 2 WO 6 with large specific surface area was synthesized by solvothermal method. • Ag 2 S quantum dot sensitized TiO 2 @Bi 2 WO 6 achieved highly sensitive detection of SARS-COV-2 nucleocapsid protein. • This PEC immunosensor showed wide range and a low detection limit. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a cluster of β coronaviruses. The 2019 coronavirus disease (COVID-19) caused by SARS-COV-2 is emerging as a global pandemic. Thus, early diagnosis of SARS-COV-2 is essential to prevent severe outbreaks of the disease. In this experiment, a novel label-free photoelectrochemical (PEC) immunosensor was obtained based on silver sulfide (Ag 2 S) sensitized titanium dioxide@bismuth tungstate (TiO 2 @Bi 2 WO 6) nanocomposite for quantitative detection of SARS-COV-2 nucleocapsid protein. The constructed TiO 2 @Bi 2 WO 6 hollow microspheres had large specific surface area and could produce high photocurrent intensity under visible light illumination. Ag 2 S was in-situ grown on the surface of thioglycolic acid (TGA) modified TiO 2 @Bi 2 WO 6. In particular, TiO 2 @Bi 2 WO 6 and Ag 2 S formed a good energy level match, which could effectively enhance the photocurrent conversion efficiency and strength the photocurrent response. Ascorbic acid (AA) acted as an effective electron donor to effectively eliminate photogenerated holes. Under optimal experimental conditions, the constructed immunosensor presented a supersensitive response to SARS-COV-2 nucleocapsid protein, with a desirable linear relationship ranged from 0.001 to 50 ng/mL for nucleocapsid protein and a lower detection limit of 0.38 pg/mL. The fabricated sensor exhibited a wide linear range, excellent selectivity, specificity and stability, which provided a valuable referential idea for the detection of SARS-COV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.
- Author
-
Zhou, Runhong, To, Kelvin Kai-Wang, Wong, Yik-Chun, Liu, Li, Zhou, Biao, Li, Xin, Huang, Haode, Mo, Yufei, Luk, Tsz-Yat, Lau, Thomas Tsz-Kan, Yeung, Pauline, Chan, Wai-Ming, Wu, Alan Ka-Lun, Lung, Kwok-Cheung, Tsang, Owen Tak-Yin, Leung, Wai-Shing, Hung, Ivan Fan-Ngai, Yuen, Kwok-Yung, and Chen, Zhiwei
- Subjects
- *
T cells , *SARS-CoV-2 , *DENDRITIC cells , *PATHOLOGY , *COVID-19 - Abstract
The SARS-CoV-2 pandemic has resulted in millions of infections, yet the role of host immune responses in early COVID-19 pathogenesis remains unclear. By investigating 17 acute and 24 convalescent patients, we found that acute SARS-CoV-2 infection resulted in broad immune cell reduction including T, natural killer, monocyte, and dendritic cells (DCs). DCs were significantly reduced with functional impairment, and ratios of conventional DCs to plasmacytoid DCs were increased among acute severe patients. Besides lymphocytopenia, although neutralizing antibodies were rapidly and abundantly generated in patients, there were delayed receptor binding domain (RBD)- and nucleocapsid protein (NP)-specific T cell responses during the first 3 weeks after symptoms onset. Moreover, acute RBD- and NP-specific T cell responses included relatively more CD4 T cells than CD8 T cells. Our findings provided evidence that impaired DCs, together with timely inverted strong antibody but weak CD8 T cell responses, could contribute to acute COVID-19 pathogenesis and have implications for vaccine development. • Acute SARS-CoV-2 infection results in broad immune cell reduction • Both dendritic cells and T cells are functionally impaired • Neutralizing antibodies are rapidly and abundantly generated • RBD- and NP-specific T cells are delayed at the acute stage COVID-19 is an acute disease caused by SARS-CoV-2 infection. We determine how the immune system responds to SARS-CoV-2 at both acute and convalescent stages. Acute SARS-CoV-2 infection results in broad immune cell reduction and functional impairment. While neutralizing antibodies are rapidly generated, antigen-specific T cells are delayed at the acute stage. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.